AstraZeneca seeks to move past China probe with Beijing R&D hub
HONG KONG, LONDON] Ever since AstraZeneca shocked investors in October with news its China chief was under investigation, the British pharmaceutical giant has tried to maintain a business-as-usual stance in its second-biggest market.
The investments come amid an ongoing investment fraud probe into AstraZeneca’s former China head Leon Wang—and despite ...
1don MSN
Foreign CEOs including Tim Cook of Apple as well as U.S. Republican Sen. Steve Daines are in Beijing for the two-day China ...
Beijing assures US and other foreign business leaders that it will continue to open its market to investments and ...
Beijing: AstraZeneca has announced an investment of USD 2.5 billion in Beijing to establish its sixth global strategic R&D ...
Multinational pharmaceutical company AstraZeneca is bullish about China's role as a global innovation powerhouse, underpinned ...
AstraZeneca's five-year US$2.5 billion investment, announced on Friday, includes a new research-and-development center in Beijing and a research agreement with Harbour BioMed. The U.K. firm will also ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback